Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants - 05/06/24
, Takahiro Sato, PhD b, Carol Ní Chaoimh, PhD c, d, Thierry Oddos, PhD a, Richard Insel, MD b, Jonathan O’B. Hourihane, MB, DM d, e, Alan D. Irvine, MD, DSc fAbstract |
Background |
The Short-Term Topical Application for Prevention of Atopic Dermatitis (STOP AD) study, a randomized, open-label trial evaluating the effect of short-term (from the first 4 postnatal days to age 8 weeks) skin barrier protection using Aveeno Dermexa Fast & Long-Lasting Balm (Johnson & Johnson, New Brunswick, NJ) in infants with a parent with allergic disease, demonstrated decreased cumulative incidence and decreased prevalence of atopic dermatitis (AD) at age 12 months.
Objective |
In the STOP AD study, we aimed to identify skin biomarkers that are associated with risk of development of AD.
Methods |
Skin swabs were collected from the cheek and antecubital fossa (AF) at baseline, age 8 weeks, and age 12 months from subsets of study participants from the intervention arm (n = 43 of 119) and control arm (n = 43 of 138) and were analyzed for specific cytokines (CCL27, CXCL2, human β-defensin-1 [hBD-1], IL-18, IL-8, IL-1α, IL-1 receptor antagonist [IL-1RA], IL-1β, S100A8/9, and IL-36γ) by ELISA.
Results |
Higher titers of S100A8/9 at the AF at age 8 weeks in infants with the filaggrin wild-type genotype (FLGwt), but not in those with filaggrin loss-of-function mutation (FLGmut), predicted (1) development of AD in the first year of life (P = .033), (2) presence of AD at ages 6 or 12 months (P = .009 and .035, respectively), (3) persistence of AD between ages 6 and 12 months (P < .001), and (4) development of AD with the emollient intervention.
Conclusion |
Increased titers of S100A8/9 from skin swabs of the AF in high-risk infants at age 8 weeks with FLGwt were predictive of AD development in the first year of life and other AD features. These findings suggest that there are different molecular pathways leading to AD in individuals with FLGmut and in individuals with FLGwt. Early identification of infants who are likely to develop AD will allow more targeted interventions.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis, biomarker, prediction, skin barrier, emollient
Abbreviations used : AD, AF, AUC, CCL27, CXCL2, FLGmut, FLGwt, hBD-1, IL-1RA, ROC, STOP AD, TEWL
Plan
Vol 153 - N° 6
P. 1597 - juin 2024 Retour au numéro
Article précédent
- IgE to cyclophilins in pollen-allergic children: Epidemiologic, clinical, and diagnostic relevance of a neglected panallergen
- Paolo Maria Matricardi, Ekaterina Potapova, Valentina Panetta, Jonas Lidholm, Lars Mattsson, Enrico Scala, Roberto Bernardini, Carlo Caffarelli, Antonella Casani, Rosa Cervone, Loredana Chini, Pasquale Comberiati, Giovanna De Castro, Michele Miraglia del Giudice, Iride Dello Iacono, Andrea Di Rienzo Businco, Marcella Gallucci, Arianna Giannetti, Viviana Moschese, Elena Varin, Annamaria Bianchi, Mauro Calvani, Tullio Frediani, Francesco Macrì, Nunzia Maiello, Francesco Paravati, Umberto Pelosi, Diego Peroni, Giuseppe Pingitore, Mariangela Tosca, Anna Maria Zicari, Giampaolo Ricci, Riccardo Asero, Salvatore Tripodi, Italian Pediatric Allergy Network
- Atopic dermatitis phenotype affects expression of atopic diseases despite similar mononuclear cell cytokine response
- Mohamed H. Taki, Kristine E. Lee, Ronald Gangnon, James E. Gern, Robert F. Lemanske, Daniel J. Jackson, Anne Marie Singh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?